Funding for this research was provided by:
Text and Data Mining valid from 2018-05-07
Received: 20 October 2017
Accepted: 24 April 2018
First Online: 7 May 2018
Compliance with ethical standards
: M. Kuchimanchi, S.M. Wasserman, and S. Doshi are employees of and stockholders in Amgen Inc. R. Somaratne and J.P. Gibbs are identified as inventors on at least one pending patent application owned by Amgen Inc. relating to evolocumab. S.M. Wasserman appears on a number of pending patents owned by Amgen Inc. relating to evolocumab and PCSK9 inhibition. J.P. Gibbs, A. Grover, and M.G. Emery were employees of and stockholders in Amgen at the time this work was completed. J.P. Gibbs is currently employed by AbbVie, Inc. A. Grover is currently employed by BioMarin Pharmaceutical Inc. M.G. Emery is currently employed by Seattle Genetics. R. Somaratne is a stockholder of Amgen, was employed by Amgen at the time this work was completed, and is currently employed by NGM Biopharmaceuticals.
: All studies were conducted in accordance with principles for human experimentation as defined in the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines, and approved by the relevant institutional review boards.
: Informed consent was obtained from each study participant after they were told of the potential risks and benefits as well as the investigational nature of the study.